Finanzen von Trinity Biotech PLC (TRIB)TRIBTrinity Biotech PLC

Evaluating the bottom line, Trinity Biotech PLC maintains a gross margin of 35.21%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -11.79%, while the net margin is -157.84%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively TRIB converts its operational activities into shareholder value.

In the context of the broader market, TRIB competes directly with industry leaders such as NXL and VNRX. With a market capitalization of $7.88M, it holds a leading position in the sector. When comparing efficiency, TRIB's gross margin of 35.21% stands against NXL's 73.16% and VNRX's 100.00%. Such benchmarking helps identify whether Trinity Biotech PLC is trading at a premium or discount relative to its financial performance.

Trinity Biotech has shown significant financial struggles, with total revenues fluctuating and a net income consistently in the negative, such as -$17.48 million in the latest quarter. The gross margin has varied, with the most recent at 35.21%, indicating some operational efficiency but not enough to offset losses.